Lithium stabilizes mood through several overlapping biological mechanisms, not just one. It blocks a key enzyme involved in brain cell signaling, shifts the balance between excitatory and calming neurotransmitters, protects neurons from damage, and even resets disrupted circadian rhythms. No single mechanism fully explains its effectiveness, which is part of why lithium remains unique among psychiatric medications more than 70 years after its introduction.
Blocking the GSK-3 Enzyme
The best-supported explanation for lithium’s mood-stabilizing effects centers on an enzyme called GSK-3. This enzyme acts like a master regulator inside brain cells, influencing gene expression, inflammation, cell structure, and how neurons communicate with each other. In bipolar disorder and depression, GSK-3 appears to be overactive, and lithium directly inhibits it.
When GSK-3 runs unchecked, it triggers a cascade of problems. It inactivates a protein called CREB, which cells need to produce growth factors and anti-inflammatory molecules. With CREB shut down, the brain makes less BDNF (a protein essential for neuron growth and flexibility) and more inflammatory compounds. Lithium reverses this by blocking GSK-3, which reactivates CREB and tips the balance toward brain cell repair and reduced inflammation.
GSK-3 also disrupts the physical infrastructure inside neurons. It breaks down microtubules, the tiny structural rails that carry cargo from one part of a nerve cell to another. When GSK-3 phosphorylates certain structural proteins, it shortens neuron branches and blocks the delivery of important molecules along axons. By inhibiting GSK-3, lithium helps restore microtubule stability and keeps intracellular transport running. In animal studies, this GSK-3 inhibition also increased the number of certain glutamate receptors on cell surfaces, which was associated with improvements in both mania-like and depression-like behaviors.
Rebalancing Excitatory and Calming Signals
Lithium shifts the brain’s neurotransmitter balance in a direction that calms overactive circuits without sedating them entirely. It suppresses dopamine and glutamate transmission (the brain’s primary excitatory signals) while boosting GABA, the main calming neurotransmitter. This dual action helps explain why lithium works against both the highs of mania and the lows of depression, rather than just pushing mood in one direction.
On the excitatory side, lithium protects neurons from glutamate-driven damage. When glutamate signaling is excessive, calcium floods into cells through NMDA receptors, which can injure or kill them. Lithium reduces this calcium influx, acting as a brake on excitotoxicity. It also regulates how AMPA glutamate receptors move in and out of cell membranes, further fine-tuning excitatory signaling.
On the calming side, lithium increases GABA release through a mechanism that doesn’t depend on the neuron firing. Lab studies show that lithium boosts the frequency of inhibitory signals at synapses in a concentration-dependent way, meaning higher lithium levels produce a stronger calming effect. This presynaptic mechanism operates independently of normal nerve impulses, which may explain why lithium’s mood-stabilizing effects persist steadily rather than fluctuating with moment-to-moment brain activity.
Protecting Brain Cells From Damage
People with bipolar disorder tend to show regional reductions in brain volume and persistent drops in neurotrophic factors, the proteins that keep neurons alive and help them form new connections. Serum levels of BDNF are lower in bipolar patients, and this deficit is thought to contribute to the progressive cognitive and structural changes seen over time.
Lithium counteracts this in two ways. First, chronic lithium treatment increases intracellular BDNF protein levels in neurons. This effect takes time to develop; acute, short-term exposure doesn’t produce the same increase, which aligns with the clinical observation that lithium’s full benefits emerge over weeks. Second, lithium markedly increases levels of Bcl-2, a protein widely regarded as one of the brain’s major protective molecules. In animal studies, Bcl-2 levels rose in the frontal cortex, hippocampus, and striatum at lithium blood levels as low as 0.3 mM, well within the therapeutic range used in humans. Bcl-2 not only shields neurons from various types of damage but also promotes regeneration of nerve fibers in the central nervous system.
Resetting Circadian Rhythms
Disrupted sleep-wake cycles are a hallmark of bipolar disorder, often preceding mood episodes. Lithium directly affects the molecular clock that governs circadian rhythms. In both animals and humans, lithium lengthens the circadian period, the internal day length that governs when you feel awake and when you feel sleepy.
At the gene level, lithium increases the expression of Per2 and Cry1, two core clock genes, while reducing expression of several others including Per3, Cry2, and Bmal1. It also extends the cycling period of Per2, essentially slowing down the molecular clock. These changes may help stabilize the erratic sleep-wake patterns that destabilize mood in bipolar disorder. Since GSK-3 itself is involved in regulating clock gene activity, this circadian effect is likely another downstream consequence of lithium’s enzyme-blocking action rather than a separate mechanism.
Reducing the Inositol Signal
One of the earliest proposed explanations for lithium’s effects, dating back over 35 years, involves a molecule called inositol. Inositol is a simple sugar that forms the backbone of several important signaling molecules inside cells. Lithium reduces the cellular concentration of inositol, which dampens a specific signaling pathway that neurons use to amplify incoming signals. The idea is that overactive inositol signaling drives the extreme mood states of bipolar disorder, and lithium turns down the volume. This “inositol depletion hypothesis” has been refined over the decades and newer research has added complexity to it, but it has never been definitively proven or ruled out.
Reducing Suicide Risk
Lithium has a well-documented ability to reduce suicidal behavior that appears to go beyond simply treating mood episodes. Compared with placebo, lithium is associated with fewer suicide attempts and fewer deaths from all causes. One proposed explanation involves serotonin: people at risk for suicide tend to have lower brain levels of tryptophan and serotonin, and lithium has serotonin-boosting properties that may counteract this deficit. Combined with its effects on GABA and glutamate, this serotonin modulation may reduce the impulsivity and emotional intensity that drive suicidal crises.
How Quickly It Works
Lithium is not fast-acting in the way that sedatives or anti-anxiety medications are. In clinical studies of acute mania, about one-third of patients showed meaningful improvement within the first week, defined as at least a 20% reduction in mania scores. By the end of four weeks, 63% had responded with a 50% or greater improvement. Early response turned out to be a strong predictor: 79% of people who improved in week one went on to have a robust response, while only 23% of those who hadn’t improved by week one eventually responded.
The neuroprotective effects take even longer. The increases in BDNF and Bcl-2 that protect brain cells require chronic treatment to develop. This is why lithium is prescribed as a long-term maintenance medication rather than something taken only during mood episodes. The therapeutic blood level is typically maintained between 0.8 and 1.2 mEq/L during acute treatment and 0.8 to 1.0 mEq/L for ongoing maintenance, requiring regular blood draws to stay within this narrow window.
Why Monitoring Matters
The same narrow therapeutic range that makes lithium effective also makes ongoing monitoring essential. Lithium can affect thyroid function, with some patients developing an underactive thyroid over time. It can also gradually reduce kidney function, though recent evidence suggests that lower lithium levels and regular kidney monitoring have substantially reduced the risk of serious kidney disease compared to earlier decades of use. Clinical guidelines recommend periodic blood tests to check thyroid hormone levels and kidney filtration rate throughout treatment. These side effects are manageable when caught early, which is why lithium requires a level of medical follow-up that most psychiatric medications do not.